Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD

Neurology. 2021 Feb 9;96(6):295-296. doi: 10.1212/WNL.0000000000011403.

Authors

Helene Zephir¹, Julien Poupart¹, Romain Deschamps², Bertrand Audoin³, Jonathan Ciron⁴, Elisabeth Maillart², Caroline Papeix², Nicolas Collongues⁵, Bertrand Bourre⁶, Mickaël Cohen⁷, Sandrine Wiertlewski⁸, Olivier Outteryck¹, David Laplaud⁸, Sandra Vukusic⁹, Romain Marignier⁹, Jonathan Giovannelli¹

Affiliations

¹ (Lille, France).
² (Paris).
³ (Marseille, France).
⁴ (Toulouse, France).
⁵ (Strasbourg, France).
⁶ (Rouen, France).
⁷ (Nice, France).
⁸ (Nantes, France).
⁹ (Lyon, France).

PMID: 33558403
DOI: 10.1212/WNL.0000000000011403

No abstract available

Publication types

Comment

MeSH terms

Aquaporin 4
Humans
Neuromyelitis Optica*

Substances

Aquaporin 4